Á. Quintana

Most-cited papers

1. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review

   J. Alijotas-Reig, E. Esteve-Valverde, C. Belizna, A. Selva-O'Callaghan +5 more

   2020Autoimmunity Reviews211 citations Open access

   Semantic Scholar

   Save

2. Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy

   Paulina Czajka-Francuz, Maria J. Prendes, A. Mankan, Á. Quintana +9 more

   2023Frontiers in Oncology62 citations Open access

   Semantic Scholar

   Save

3. Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor-induced myositis

   I. Pinal-Fernández, Á. Quintana, J. Milisenda, M. Casal-Domínguez +26 more

   2022Annals of the Rheumatic Diseases56 citations Open access

   Semantic Scholar

   Save

4. B Cells in Breast Cancer Pathology

   Mengyuan Li, Á. Quintana, E. Alberts, Shing-Hung Miu +3 more

   2023Cancers34 citations Open access

   Semantic Scholar

   Save

5. Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy

   K. Saini, Sasikala Somara, H. Ko, P. Thatai +19 more

   2024Frontiers in Oncology27 citations Open access

   Semantic Scholar

   Save

6. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer.

   Idoko Salifu, Navneet Singh, M. Berraondo, J. Remon +8 more

   2023Cancer Treatment and Research Communications24 citations Open access

   Semantic Scholar

   Save

7. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer.

   Á. Quintana, V. Peg, A. Prat, T. Moliné +14 more

   2021European Journal of Cancer18 citations Open access

   Semantic Scholar

   Save

8. Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer

   Á. Quintana, K. Saini, L. Vidal, V. Peg +5 more

   2024ESMO Open16 citations Open access

   Semantic Scholar

   Save

9. Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune-checkpoint inhibitors.

   R. Morales-Barrera, C. Suárez Rodriguez, Macarena González, J. Ros +15 more

   2019Journal of Clinical Oncology9 citations

   Semantic Scholar

   Save

10. Evaluation of triple negative breast cancer with heterogeneous immune infiltration

    Á. Quintana, E. Arenas, C. Bernadó, J. F. Navarro +9 more

    2023Frontiers in Immunology8 citations Open access

    Semantic Scholar

    Save

11. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    K. El Bairi, H. R. Haynes, E. Blackley, S. Fineberg +496 more

    2021npj Breast Cancer2 citations Open access

    Semantic Scholar

    Save

12. 33P Immune analysis of lymph nodes in relation to the presence or absence of tumour infiltrating lymphocytes in triple negative breast cancers

    Á. Quintana, V. Peg, T. Moliné, A. Prat +12 more

    20201 citations Open access

    Semantic Scholar

    Save

13. Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors

    R. Barrera, I. Matos, M. González, C. Suárez +13 more

    2019Annals of Oncology1 citations Open access

    Semantic Scholar

    Save

14. Genetic Alterations In Patients With Chronic Myeloid Leukemia And Their Association With The Development Of Cardiovascular Events According To The Use Of Tyrosine Kinase Inhibitors

    M. N. Saez Perdomo, C. B. Sieyro, G. Jose, E. Pérez +10 more

    20190 citations

    Semantic Scholar

    Save